Here’s a list of SIM01 studies:
A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, doubleblind, placebo-controlled trial
- https://www.thelancet.com/action/showPdf?pii=S1473-3099(23)00685-0
→ The recruitment page for RECOVERY can be found here via archive.org. The Google translation is: “Suitable candidates will be invited to take probiotics or vitamins for 6 months”. This suggests an active placebo… perhaps higher than 1mg vitamin C. - This study was cited by an editorial comment posted in Lancet Infectious Diseases.
Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study).
- Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) - PMC
- Pre-registration: ClinicalTrials.gov
- NOTE: The pre-registration for the IMPACT study also shows that the primary endpoint was changed. See here.
Those first two are used by GenieBiome / G-NiiB to advertise its SIM01 product.
LONGITUDINAL MULTI-OMICS REVEALS MECHANISMS UNDERLYING BENEFICIAL EFFECTS OF A NOVEL MICROBIOME IMMUNITY FORMULA (SIM01) IN COVID-19 PATIENTS
https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1967239
Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study
- https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.15796
- Pre-registration (NCT04581018) at ClinicalTrials.gov
A Probiotic Formula for Modulation of Colorectal Cancer Risk via Reducing CRC-Associated Bacteria
- A Probiotic Formula for Modulation of Colorectal Cancer Risk via Reducing CRC-Associated Bacteria - PubMed
- Pre-registration (NCT04581018) was the same as another study. Available at ClinicalTrials.gov
Commercial ties
The CUHK website promotes the work on SIM01, which was “developed by CUHK”.
This paper states:
Prof. Siew Ng and Prof. Francis Chan report serving as founder member for GenieBiome Limited
The G-NiiB website has information on where to buy SIM01. The advisors webpage lists Martin Wong of the CUHK, who appears in the CUHK website promoting SIM01. Martin Wong is the lead author of the IMPACT study.